Bacillus cereus is Able to Resist Certain Antibiotic Therapies
News Jan 04, 2016
The pathogenic bacterium Bacillus cereus causes vomiting and diarrhoea as well as systemic and local infections such as sepsis or eye infections. A team from the Vetmeduni Vienna has now reported for the first time that B. cereus, following contact with certain antibiotics, can switch into a special slowed-down mode. The bacteria then form small colony variants (SVCs) that are difficult to diagnose and almost impossible to treat with certain antibiotics. This newly discovered mechanism may provide an alternative explanation for antibiotic resistance.
The bacterium B. cereus had so far been considered to be exclusively endospore-forming. In response to harsh conditions, the bacteria form protective endospores enabling them to remain dormant for extended periods. When conditions are more favourable, the endospores reactivate to become fully functioning bacteria.
Elrike Frenzel, Markus Kranzler and Monika Ehling-Schulz of the Institute of Microbiology at the University of Veterinary Medicine Vienna have now shown for the first time that B. cereus has an alternative lifestyle in the form of so called small colony variants (SCVs). In B. cereus these SCVs form in response to exposure with aminoglycoside antibiotics. SCVs grow slower than the original form of B. cereus. They have an altered metabolism and are resistant to those antibiotics which triggered this state, namely aminoglycosides.
“The bacterium protects itself against the harmful effects of the antibiotics by forming these Small Colony Variants. But B. cereus is usually treated with exactly those antibiotics which induce the SCV state. If an antibiotic triggers the formation of SCVs, it also triggers resistance,” first author Frenzel explains.
Rethinking therapy and diagnostics
The mechanism discovered by Frenzel, Kranzler and Ehling-Schulz is of enormous significance in clinical practice. Traditional diagnostic methods are based on the identification of metabolic features of B. cereus. These tests will not detect SCVs, however, as they have a slower, altered metabolism. This may result in incorrect antibiotic therapies or even failed diagnoses. Study author Frenzel sees molecular-based diagnostics as the only way to diagnose this form of B. cereus.
Treating B. cereus infections using only aminoglycoside antibiotics could bear the risk of a prolonged infection. SCVs grow more slowly, but they still produce toxins that are harmful to the body. “In this case, a combination therapy with other antibiotic groups is advisable,” Frenzel recommends.
New molecular mechanism of SCV formation
One species of bacteria that has been known for years to be a multiresistant hospital pathogen and which poses a life-threatening risk for immunocompromised individuals in particular is Staphylococcus aureus. Those bacteria also form SCVs, but unlike B. cereus they are capable of reverting to its original state. For B. cereus, the adaptation to a small colony variant appears to be final. “We believe that the SCV formation in B. cereus functions differently than in S. aureus,” says study author Ehling-Schulz.
Environmental niche to cope with stress
“The ability to form SCVs appears to be of environmental significance for the bacteria,” Frenzel believes. “This alternative lifestyle allows the bacteria to avoid threatening stress factors such as antibiotic exposure. B. cereus are soil-dwelling, and other microorganism in the soil produce antibiotics. Here, too, the formation of SCVs would be an advantage for the bacteria.”
Biomarkers Could Produce Preeclampsia Diagnostic TestNews
Small non-coding RNA analysis may revolutionize how doctors assess preeclampsia risk.READ MORE
Shire, Microsoft and EURORDIS Form Global Commission to Accelerate Rare Disease DiagnosisNews
The alliance aims to shorten the often multi-year journey that patients and families endure before being diagnosed with a rare disease.READ MORE
Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast CancerNews
A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer.READ MORE